The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTrifast Regulatory News (TRI)

Share Price Information for Trifast (TRI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 77.00
Bid: 77.20
Ask: 80.80
Change: -4.00 (-4.94%)
Spread: 3.60 (4.663%)
Open: 77.20
High: 77.20
Low: 77.00
Prev. Close: 81.00
TRI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

22 Jan 2024 07:00

RNS Number : 3740A
Trifast PLC
22 January 2024
 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

 

London, Monday 22 January 2024

 

 

TRIFAST PLC

(Trifast, Group or Company)

 

Leading international specialist in the design, engineering, manufacture, and distribution

of high-quality industrial fastenings and Category 'C' components principally to major global assembly industries

 

Trading update

 

 

Market conditions during Q3 saw a continuation of the trends described in the Group's interim results, published on 21 November 2023, characterised by low visibility and volatile demand in a number of end market and geographic segments. Disappointingly, performance in December 2023 was impacted by significantly lower than forecasted volumes in both our Asia operations and global distribution sales channel. Whilst we had anticipated both of these areas to see a recovery from subdued activity in H1, demand conditions and excess customer inventory levels have pushed this recovery further into 2024 and we now expect these challenging conditions to persist through to the end of the financial year.

As set out in the interim results and in spite of the difficult backdrop, management have continued to focus on the Operational Improvement programme instigated in 2023 to drive improved efficiency and productivity for HY2 and beyond. Whilst good progress has been made in reducing cost in a number of areas, this will not be enough to mitigate the impact of the lower revenue expectation for the second half. Consequently, the Board now expects that the Group's results for the year ending 31 March 2024 to be significantly below its previous expectations, with revised revenue at c.£230m and adjusted EBIT margin percentage of c.5%.

The more testing environment that we are now experiencing in 2024 in terms of growth is being severely impacted by a further slowdown in customer demand and volumes across the business and to an extent by the reported macro-economic challenges and geopolitical events.

As a consequence of the prevailing markets, continued weak economic outlook and the impact of this on the business we have accelerated our recovery action plan, including a Group restructuring programme to further reduce operating cost through a c.10% cutback in our non-operational staff globally. This programme is expected to deliver additional annualised savings of c.£3m. As part of the restructure, we will establish a leaner organisational structure to enable faster decision making. In parallel, we are undertaking a strategic review of our global footprint to identify further cost efficiencies which will reset our business for the future.

As we previously announced, working capital and cash management remain a key focus; we predict to effectively reduce leverage below 1.5x and Group net debt to be below our target of £25m. Our UK National Distribution Centre and Atlas projects are, as previously committed, on track to be completed by the end of March 2024.

As a Group, the Balance sheet remains strong, we continue to see significant scope to rebuild and invest in the business and we remain confident in the fundamentals of our business model over the medium-term.

 

We will provide more detail on the restructuring, strategic plans and progress at the time of the Group's annual results scheduled to be released in July 2024.

 

 

*Consensus forecasts FY24 prior to this announcement were revenue of £254m adjusted EBIT £15.5m

 

Enquiries please contact:

Trifast plc

Serena Lang, Non-Executive Chair

Iain Percival, Chief Executive Officer

Darren Hayes-Powell, Chief Financial Officer

Office: +44 (0) 1825 747630

Email: corporate.enquiries@trifast.com

Shareholders: companysecretariat@trifast.com

Peel Hunt LLP (Stockbroker & financial adviser)

Mike Bell

Tel: +44 (0)20 7418 8900

TooleyStreet Communications (IR & media relations)

Fiona Tooley

Tel : +44 (0)7785 703523

Email: fiona@tooleystreet.com

 

 

Editors' notes

 

About Trifast plc (TR)

Founded in East Sussex in 1973, TR is a leading international specialist in the design, engineering, manufacture, and distribution of high-quality industrial fastenings and Category 'C' components principally to major global assembly industries.

 

The Group supplies to customers in c.70 countries across a wide range of industries, including light vehicle, heavy vehicle, health & home, energy, tech, & infrastructure (ET&I), general industrial and distributors. As a full service provider to multinational OEMs and Tier 1 companies spanning several sectors, we deliver comprehensive support to our customers across every requirement, from concept design through to technical engineering consultancy, manufacturing, supply management and global logistics.

 

As an international business we are able to provide 24/7 customer support from across key regions in the UK, Asia, Europe and North America. In addition to our service locations we operate a number of manufacturing facilities focused on high volume cold forged fasteners and special parts. We have also established Technical & Innovation Centres to support R&D and customer collaboration across the world.

 

For more information, visit our

Investor website: www.trifast.com

Commercial website: www.trfastenings.com 

LinkedIn: www.linkedin.com/company/tr-fastenings

Twitter: www.twitter.com/trfastenings

Facebook: www.facebook.com/trfastenings

 

Trifast, TR and TR Fastenings are registered trademarks of the Company

 

LEI number: 213800WFIVE6RWK3CR22

 

 

Forward-looking statements

This announcement contains certain forward-looking statements. These reflect the knowledge and information available to the Company during the preparation and up to the publication of this document. By their very nature, these statements depend upon circumstances and relate to events that may occur in the future thereby involving a degree of uncertainty. Therefore, nothing in this document should be construed as a profit forecast by the Company.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFFLLLZFLEBBD
Date   Source Headline
25th Apr 20247:00 amRNSTrading update & Notice of Annual results
15th Apr 20242:11 pmRNSDirector/PDMR Shareholding
15th Apr 20241:07 pmRNSDirector/PDMR Shareholding
4th Apr 202410:40 amRNSBlock listing Interim Review
21st Mar 20247:00 amRNSDirector/PDMR Shareholding - Purchase of shares
13th Mar 20242:30 pmRNSDirector/PDMR Shareholding
11th Mar 20247:00 amRNSAppointment & retirement of non-executive director
22nd Feb 20247:00 amRNSDirectorate Change
9th Feb 20247:00 amRNSHolding(s) in Company
1st Feb 202410:09 amRNSHolding(s) in Company
1st Feb 20247:00 amRNSTotal Voting Rights
31st Jan 20249:33 amRNSHolding(s) in Company
24th Jan 20247:00 amRNSDirector/PDMR Shareholding
23rd Jan 202411:23 amRNSDirector/PDMR Shareholding
22nd Jan 20243:20 pmRNSDirector/PDMR Shareholding
22nd Jan 20247:00 amRNSTrading Update
3rd Jan 20245:50 pmRNSTotal Voting Rights
21st Dec 20234:24 pmRNSHolding(s) in Company
21st Dec 20234:18 pmRNSHolding(s) in Company
15th Dec 20237:00 amRNSNon executive director retirement update
1st Dec 20237:00 amRNSDirector/PDMR Shareholding
30th Nov 20237:00 amRNSPDMR - Performance conditions for LTIP award
24th Nov 20232:34 pmRNSDirector/PDMR shareholding - Purchase of shares
21st Nov 20237:00 amRNSHalf-year Report - six months to 30 September 2023
24th Oct 20237:00 amRNSHalf year trading update and notice of results
19th Oct 20237:00 amRNSNon-executive Director appointment
12th Oct 20237:00 amRNSDirectorate retirement
3rd Oct 20234:16 pmRNSBlock listing Interim Review
25th Sep 20233:49 pmRNSHolding(s) in Company
19th Sep 20234:45 pmRNSPDMR Save As You Earn Plan grant of Option
15th Sep 20233:05 pmRNSResult of AGM
15th Sep 20239:15 amRNSCEO appointment
14th Sep 20234:48 pmRNSDirectorate Change
29th Aug 20237:00 amRNSHolding(s) in Company
10th Aug 20237:00 amRNSBoard Appointment
3rd Aug 202311:36 amRNSDirector/PDMR Shareholding
19th Jul 20232:31 pmRNSHolding(s) in Company
19th Jul 20237:00 amRNSAR posting - AGM - Sustainability report & TVR
17th Jul 20231:25 pmRNSHolding(s) in Company
11th Jul 20237:00 amRNSAnnual results - 31 March 2023 - Annual Report
9th Jun 20237:00 amRNSNotice of Annual Results
10th May 202311:38 amRNSHolding(s) in Company
4th May 20233:50 pmRNSDirector Declaration
26th Apr 20237:00 amRNSTrading update
4th Apr 20234:45 pmRNSTotal Voting Rights
4th Apr 20234:43 pmRNSBlock listing Interim Review
29th Mar 20234:47 pmRNSHolding(s) in Company
28th Feb 20236:16 pmRNSPDMR Shareholding
28th Feb 20231:38 pmRNSDirector/PDMR Shareholdings
27th Feb 20233:14 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.